Deka Biosciences
Developing life-changing and enabling medicines for patients with cancer and inflammatory diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
* | N/A | $30.0m | Late VC |
| Total Funding | 000k | ||
Related Content
Deka BioSciences, Inc. is a biotechnology company focused on developing and delivering transformative medicines for patients suffering from cancer and inflammatory diseases. The company leverages the natural properties of cytokines, specifically IL-10 and IL-4, to enhance their anti-inflammatory functions and target tumor microenvironments effectively. By combining these cytokines, Deka BioSciences aims to suppress inflammatory responses and improve the efficacy of cancer treatments. The company operates in the biopharmaceutical market, serving patients with conditions such as sepsis, psoriasis, and rheumatoid arthritis. Deka BioSciences generates revenue through the development and commercialization of its proprietary medicines, targeting both domestic and global markets. The business model includes research and development, clinical trials, and partnerships with healthcare providers and pharmaceutical companies.
Keywords: biotechnology, cytokines, cancer treatment, inflammatory diseases, IL-10, IL-4, tumor microenvironment, sepsis, psoriasis, rheumatoid arthritis.